InvestmentPitch Media Video Discusses FSD Pharma's Definitive Agreement to Acquire 100% of Lucid Psycheceuticals Inc. - Video Available on Investmentpitch.com

About this update from Quantum Biopharma Ltd. Subordinate Voting Shares Class B

[{"type":"text","content":"InvestmentPitch Media Video Discusses FSD Pharma's Definitive Agreement to Acquire 100% of Lucid Psycheceuticals Inc. - Video Available on Investmentpitch.comVancouver, British Columbia--(Newsfile Corp. - August 26, 2021) - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions in legal psychedelics and medical cannabis, has signed a definitive agreement to acquire 100% of Lucid Psycheceuticals Inc.Founded in 2020, Lucid Psycheceuticals (www.LucidPsycheceuticals.com), a Canadian-based specialty psychedelic pharmaceutical company, is developing novel molecules and combinations with the goal of addressing Total Brain Health and targeting some of the most challenging neurodegenerative diseases, such as Multiple Sclerosis, and other brain conditions.Cannot view this video? Visit:http://www.investmentpitch.com/video/1_brzd97fy/FSD-Pharma-signs-definitive-agreement-to-acquire-100-of-Lucid-Psycheceuticals-Inc.InvestmentPitch.com has produced a \"video\" which discusses this news. If this link is not enabled, please visit www.InvestmentPitch.com and enter \"FSD Pharma\" in the search box.Lucid has exclusive worldwide licensing rights from the University Health Network, North America's largest health research organization, to a patent-protected family of new chemical entities (NCEs), on which Lucid's development platform is based and from which its lead neurodegenerative disorders therapeutic candidate, Lucid-21-302, has been derived. In addition, Lucid's pipeline includes Lucid-201, a psychedelic drug candidate targeting mental health disorders, and it is also investigating certain cannabinoids.Anthony Durkacz, Interim CEO, stated \"The acquisition of a distinctive company like Lucid illustrates FSD Pharma's vision to build a portfolio of biotechnology assets on a new frontier of medicine that hold the potential to treat mental health disorders and neurodegenerative diseases in a new way. Lucid has successfully developed a strong pipeline of novel therapeutic compounds - supported by IP in order to advance to future clinical trials - and we are confident that the experience the Lucid leadership team brings will allow us to immediately start the process towards clinical trials to further advance these promising therapies. This is an excitin...

More updates from Quantum Biopharma Ltd. Subordinate Voting Shares Class B